The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Zepzelca (lurbinectedin) on October 2, 2025. This approval, designated as NDA 213702 S-11, specifically addresses the drug's efficacy. The supplemental new drug application was sponsored by JAZZ Pharmaceuticals.
Background
A supplemental application, such as this one for Zepzelca, is typically submitted to the FDA to propose changes to an already approved drug. These changes can include updates to dosing, manufacturing, or, as in this case, further information or confirmation regarding the drug's efficacy. An efficacy approval indicates that the FDA has reviewed data supporting the drug's ability to produce the intended therapeutic effect for its approved use. The sponsor for this application is JAZZ Pharmaceuticals.
What this means
This supplemental approval for Zepzelca (lurbinectedin) reinforces the scientific evidence supporting the drug's effectiveness. For clinicians, researchers, and patient advocates, this regulatory action confirms the FDA's continued assessment of the drug's benefits. It signifies that the agency has evaluated additional data related to the drug's performance in achieving its therapeutic goals, providing further assurance regarding its established or expanded utility.
Source
The information regarding this supplemental approval for Zepzelca (lurbinectedin) was obtained from the U.S. Food and Drug Administration (FDA). The approval for supplemental application NDA 213702 S-11 was recorded on October 2, 2025, and is accessible via accessdata.fda.gov.